Navigation Links
Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP
Date:12/7/2009

those patients treated with Nplate or placebo with most adverse events being mild to moderate in severity. Most frequent adverse events in patients taking Nplate or placebo were headache (35 percent vs. 40 percent, respectively), epistaxis (35 percent vs. 20 percent, respectively), cough (12 percent vs. 40 percent, respectively) and vomiting (12 percent vs. 40 percent, respectively).

Efficacy results showed that Nplate was effective in treating thrombocytopenia compared to placebo, with 88 percent of the 17 patients receiving Nplate achieving both efficacy endpoints during treatment (number of patients achieving a platelet count of over 50,000 platelets per microliter for two consecutive weeks during the treatment period and/or achieving an increase in the platelet count of 20,000 platelets per microliter above baseline for two consecutive weeks). Other observations included a decrease in rescue medication use, and numerically lower duration-adjusted bleeding adverse event rates with Nplate treatment as compared with placebo. None of the placebo-treated patients (n=5) achieved either efficacy endpoints.

Study Design

This Phase 1/2, 12-week treatment period evaluated the safety and efficacy of Nplate in the treatment of thrombocytopenia in children with chronic ITP (n=22). The study involved children with ITP aged 12 months to less than 18 years old with persistent severe thrombocytopenia for at least six months. The median age of study participants was 9.5 years. Nplate was administered subcutaneously at 1 mcg/kg once-weekly and doses were adjusted to a maximum dose of 10 mcg/kg weekly.

Results from Ongoing, Long-Term Extension Efficacy and Safety Study (Abstract #681)

Results from an ongoing, long-term extension study in adults that were also presented at the meeting showed that Nplate maintained platelet counts within a range of 50,000 to 200,000 platelets per microliter in the majority of adu
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program
2. New Amgen Scholars Web site Launches to Build a Global Network for Future Scientists
3. Amgen Highlights Data to be Presented at ASH
4. Amgen Recognized for Best Pipeline and Best New Drug at Scrip Awards
5. Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer
6. Call for Applications: The Amgen Award for Science Teaching Excellence
7. Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
8. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
9. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
10. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
11. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014  Amgen ... the submission of a Marketing Authorization Application ... via the centralized procedure for talimogene laherparepvec ... with melanoma that is regionally or distantly ... administered as an intralesional injection that is ...
(Date:9/2/2014)... FRANCISCO, Calif. , Sept. 2, 2014   Veracyte, ... Bonnie H. Anderson , president and chief executive officer, ... Morgan Stanley Global Healthcare Unplugged Conference 2014 on Monday, September ... York . The live audio webcast and ... http://investor.veracyte.com . Please connect to the website at least ...
(Date:9/2/2014)... Redspin, Inc., a leading provider of HIPAA ... an IT security advisory specifically for senior executives in ... presiding over the most dynamic period in the history ... Redspin,s President and CEO. "The goal of our advisory ... understand why they need to elevate IT security to ...
Breaking Medicine Technology:Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 2Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 3Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 4Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 5Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 6Veracyte to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2014 2
... importance of dedicated information management systems for radiation ... most recent version of its MOSAIQ® Oncology Information ... Systems Society,s 2012 conference (HIMSS12), Feb. 20-24, in ... comprehensive OIS that centralizes traditional radiation oncology, particle ...
... Feb. 16, 2012  Cardium Therapeutics (NYSE Amex: ... previously announced sale of 17,857,143 shares of its common ... of approximately $5.0 million, before deducting placement agent,s fees ... investors participating in the offering purchased the shares at ...
Cached Medicine Technology:Elekta Highlights Latest Version of MOSAIQ Oncology Information System at HIMSS12 Meeting 2Cardium Announces Closing of $5.0 Million Equity Financing 2Cardium Announces Closing of $5.0 Million Equity Financing 3
(Date:9/2/2014)... Humility of Mary Health Partners will offer a ... Health Center, 1044 Belmont Ave. , The workshop includes an ... common health problems as well as tips on caring for ... on when to seek medical attention. , The morning ... Room; the evening session runs from 5:30 to 6:30 p.m. ...
(Date:9/2/2014)... 02, 2014 A little bit of ... sometimes the onset of irritability, sadness, or apathy can ... September 2014 Harvard Health Letter. , "Mood-related ... stresses. If they occur for long periods, cause significant ... to seek help," says Dr. Nancy Donovan, an instructor ...
(Date:9/2/2014)... Eric Jimenez and Leah Ashley announced ... revolutionary makeup application device. Designed to improve and accelerate ... the palm of women’s hands to help them get ... Me’s success lies in its patented technology. With a ... 15,000 pulses per minute, the device applies foundation evenly ...
(Date:9/2/2014)... B. E. Smith, the only full-service leadership solutions ... to lead a national chief executive officer ... Sioux Falls, S.D. The top executive search firm in ... more than 900 healthcare executives into organizations. , ... and nationally recognized leader in patient-centered care. It is ...
(Date:9/2/2014)... Syracuse, NY (PRWEB) September 02, 2014 ... A. Gadlage, M.D. & Associates in Duluth, GA and ... the EarQ team at the 2014 National ... in Cancun, Mexico. , While interacting with the former ... maintaining hearing health, the team provided free hearing screenings, ...
Breaking Medicine News(10 mins):Health News:HMHP Offers ‘Health at Home’ Workshop 2Health News:When a Mood Swing Signals Trouble, From the September 2014 Harvard Health Letter 2Health News:Color Me Launches With Ulta Beauty Revolutionary Makeup Application Device Gets Women Flawless in a Flash 2Health News:Color Me Launches With Ulta Beauty Revolutionary Makeup Application Device Gets Women Flawless in a Flash 3Health News:Sioux Falls Specialty Hospital Retains B. E. Smith to Recruit New CEO 2Health News:Sioux Falls Specialty Hospital Retains B. E. Smith to Recruit New CEO 3Health News:The EarQ Team Brings Hearing Health Awareness to the 2014 National Basketball Retired Players Association Annual Convention in Cancun 2
... the number of global users outnumbering other users of ... authorities from the U.S have warned that if appropriate ... could lead to a global threat. ,Methamphetamine ... a stimulant that induces euphoria in its users. Discovered ...
... who had been bitten by a bat and subsequently diagnosed with ... observation. Although treatment is being offered, the chances of the boy ... boy, a student of Humble High School fell ill last week, ... weeks before this could happen, a bat had flown into his ...
... a novel study conducted at the University of Illinois at ... happened after the victim was drugged// and in 5% of ... 100,000 sexual assaults are committed in the United States each ... times higher if all cases were reported, said Adam Negrusz, ...
... Queeen's has suggested that patients who combine a low ... better results in clearing toxins and increasing overall physical ... of dialysis patients was recently carried out by Rehabilitation ... and Respiratory (CCR) group at Queen's, and a group ...
... conducted a joint cell and animal study that has revealed ... malaria, often causing death. ,The culprit is a protein ... to suppress red blood cell production in people whose red ... ,The parasite that causes malaria - known as plasmodium - ...
... million American adults are smokers, obese or both and are faced ... // ,Data from a 2002 national health interview ... United States who have one or both problems. ,The ... million people and this would include a larger percentage of them ...
Cached Medicine News:Health News:Meth Addiction On The Rise, US Health Authorities Concerned 2Health News:UIC Study Throws Light On Sexual Assaults 2Health News:Exercise Combined with Dialysis Yields Better Results 2Health News:Anemia from Malaria Linked to a Protein MIF 2Health News:Anemia from Malaria Linked to a Protein MIF 3
...
The Tew cranial/spinal retractor is designed for posterior fossa or intraspinal microsurgery where retraction is required. Clinical applications are: Posterior fossa microsurgery and intraspinal micr...
The Doro Halo retractor system is designed for all neurosurgical applications where retraction of the brain tissue and an armrest is required....
The Budde Halo brain retractor is designed for use in all intercranial procedures where retraction of delicate brain tissue is required....
Medicine Products: